Impact of Big Data on medicine regulatory network

Author
Published on
Category

Data Analysis and Real-World Interrogation Network (DARWIN EU®) is a federated network which gives the European medicines regulatory network access to results from analysis of data from real-world healthcare databases across the EU.
While the DARWIN EU project is primarily focused on biodiversity conservation and ecosystem restoration, it can also have important implications for the medicine regulatory network. One area where the project can have an impact is in the development of new drugs and other medical treatments.
EMA has selected the first set of data partners to collaborate within DARWIN EU. They have access to real-world healthcare data from hospitals, primary care, health insurance, biobanks and disease specific patient registries. 
One of the first three studies to be provided by the DARWIN EU® project is the investigation of the use of antibiotics to gather data on anti-microbial resistance, which is a growing problem worldwide.
Overall, though the primary focus of the DARWIN EU project is on biodiversity conservation and ecosystem restoration, its impact on the medicine regulatory network should not be overlooked.
Would you like to stay informed about news in the pharmaceutical regulatory world and increase your regulatory intelligence, please do not hesitate to contact us via the Contact form.

Explore more Updates

Windsor Framework – Changes to the licensing of medicines for human use in the UK (and affecting Northern Ireland)

Unlocking Innovation with EMA’s Innovation Task Force

The International Recognition Procedure (IRP) for Medicinal Products in the UK

Valentyna Starodub
Founder and Chief Executive Officer

Let's Connect

Talk to an expert